http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2511143-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1bde28565d28f037e78bf4a67776ee24 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C253-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D307-87 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C253-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D307-87 |
| filingDate | 2003-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e0c5e38236c939190ada3c07caa922e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_02a02a19757b09826fc9edcc59ae2d0d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_803a5a2f277256ad21983f2f8da2a724 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c75f07838a8a23c74523afb6436a2ab3 |
| publicationDate | 2004-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2511143-A1 |
| titleOfInvention | Preparation of racemic and/or s- or r-citalopram diols and their use for the preparation racemic and/or s- or r-citalopram |
| abstract | In the following, citalopram diol means 4-(4-(dimethylamino)-l~-(4-fluorophenyl)-1-hydroxybutyl)-3-(hydroxymethyl)-benzonitrile, as free base and/or acid addition salt. The invention relates to a process for the preparation of racemic citalopram diol and/or R- or S-citalopram diol, comprising the separation of a non-racemic mixture of R- and S-citalopram diol with more than 50% of one of the enantiomers into a fraction being enriched with S- or R-citalopram diol and a fraction comprising RS-citalopram diol wherein the ratio of R-citalopram diol:S-citalopram diol is equal to 1:1 or closer to 1:1 than in the initial mixture. The method is characterized in that (i) RS-citalopram diol is precipitated from a solution of the initial non-racemic mixture, or R- or S-citalopram diol is dissolved into a solvent from the initial non-racemic mixture, leaving a residue of RS-citalopram diol, and in that (ii) the residue/precipitate formed is separated from the final solution phase, followed by optional steps of repetition, recrystallisation, purification, isolation and conversion between free base and salts. The invention also relates to a process for the preparation of RS-citalopram, S-citalopram or R-citalopram (all as free base and/or acid addition salt) comprising the method described above followed by ring closure. |
| priorityDate | 2002-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 63.